🇺🇸 FDA
Pipeline program

zeleciment basivarsen (DYNE-101)

DYNE101-DM1-301

Phase 3 small_molecule active

Quick answer

zeleciment basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) is a Phase 3 program (small_molecule) at Dyne Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Dyne Therapeutics
Indication
Myotonic Dystrophy Type 1 (DM1)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials